(Q37145218)

18 August 2017

1 reference

title

The role of testosterone in the pathogenesis of prostate cancer (English)

1 reference

18 August 2017

0 references

1 reference

1 reference

1 reference

Takashi Imamoto

1

1 reference

18 August 2017

Hiroyoshi Suzuki

2

1 reference

18 August 2017

Masashi Yano

3

1 reference

18 August 2017

Koji Kawamura

4

1 reference

18 August 2017

Naoto Kamiya

5

1 reference

18 August 2017

Kazuhiro Araki

6

1 reference

18 August 2017

Akira Komiya

7

1 reference

18 August 2017

Naoki Nihei

8

1 reference

18 August 2017

Yukio Naya

9

1 reference

18 August 2017

Tomohiko Ichikawa

10

1 reference

18 August 2017

22 April 2008

1 reference

International Journal of Urology

18 August 2017

1 reference

18 August 2017

15

1 reference

18 August 2017

6

1 reference

18 August 2017

472-480

1 reference

Testosterone and prostate cancer: an historical perspective on a modern myth

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

A critical evaluation of simple methods for the estimation of free testosterone in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Evaluation of assays available to measure free testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

High-grade prostate cancer is associated with low serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Association between prostate cancer and serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Influence of radical prostatectomy on serum hormone levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Elevated expression of inhibin alpha in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Hormones and prostate cancer: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The prevention of prostate cancer--the dilemma continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Reduced circulating androgen bioactivity in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Molecular genetics of steroid 5 alpha-reductase 2 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The androgen receptor gene and its influence on the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Hormones and prostate cancer: current perspectives and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Overweight, obesity, and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Body mass index and risk of prostate cancer in U.S. health professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Risks of testosterone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Testosterone replacement therapy and the risk of prostate cancer: a perspective view

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Baseline health-related quality of life in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Estrogens and aspects of prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

Prevention of prostate cancer by androgens: experimental paradox or clinical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02074.X

10.1111/J.1442-2042.2008.02074.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference